Axoft develops ultra-soft neural implants and a brain-implant platform designed to enable stable, long-term brain-computer interfaces. The company, founded in 2021 and headquartered in Cambridge, Massachusetts, emerged from Harvard University research and focuses on bridging the gap between electronic devices and biological tissue through bioinspired materials science.
The company's core technology centres on Fleuron, a proprietary ultra-soft material that is over one million times softer than traditional rigid electronics used in brain implants. This material forms the foundation of Axoft's broader platform, which combines advanced materials, electronics, and artificial intelligence to achieve single-neuron resolution communication with any brain region. The platform claims electrode density one thousand times greater than existing soft implants and provides long-term stable neural recording and stimulation.
Axoft is currently advancing its technology through in-human clinical studies across the United States, Central America, and Asia. The company's technical work spans materials science, biomedical engineering, neuroscience, artificial intelligence, and clinical research, with a stated mission to unlock new treatments for patients with neurological disorders and physical disabilities.
